Tysabri labeling changes submitted to help stratify PML risk
Tysabri labeling changes submitted to help stratify PML risk
Biogen Idec and Elan Corporation, plc have announced that the companies have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) to request review and approval to update the respective Tysabri Prescribing Information and Summary of Product Characteristics.
The companies are proposing updated product labeling to include anti-JC Virus antibody status as one potential factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, in the Tysabri-treated population.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2310 Views
-
Last post by NHE
-
- 6 Replies
- 6605 Views
-
Last post by ElliotB
-
- 0 Replies
- 1340 Views
-
Last post by NHE
-
- 0 Replies
- 3432 Views
-
Last post by NHE
-
- 1 Replies
- 1024 Views
-
Last post by NHE
-
- 11 Replies
- 3374 Views
-
Last post by NHE
-
- 1 Replies
- 1518 Views
-
Last post by NHE
-
- 0 Replies
- 3162 Views
-
Last post by NHE
-
- 0 Replies
- 1379 Views
-
Last post by NHE